Dry Eye Flares Consensus Roundtable Chapter 3: Current an -

Eric D. Donnenfeld, MD

Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, New York

Preeya K. Gupta, MD

Founder and Director of Triangle Eye Consultants

Wake Forest and Cary, North Carolina

Terry Kim, MD

Professor of Ophthalmology
Duke University School of Medicine
Chief, Cornea and External Disease Division
Director, Refractive Surgery Service
Duke University Eye Center
Durham, NC

Richard Lindstrom, MD

Adjunct Professor Emeritus
Department of Ophthalmology
University of Minnesota
Minneapolis, Minnesota

Stephen C. Pflugfelder, MD

Professor of Ophthalmology
James and Margaret Elkins Chair
Director, Ocular Surface Center
Baylor College of Medicine

Elizabeth Yeu, MD

Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Cornea, Cataract, External Disease, and Refractive Surgery
Assistant Professor, Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, VA

Edward J. Holland, MD

Professor of Ophthalmology
University of Cincinnati
Director, Cornea Service
Cincinnati Eye Institute
Cincinnati, Ohio

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan , Alcon Vision, Avellino Labs, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharma, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharma, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus Therapeutics. Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharma Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations Oculis, Orasis Pogotec, RegenerEyes, ReTear, RPS , Strathspey Crown, Surface, Tarsus, Tearlab, Veracity, Versant Ventures, Visionary Ventures, and Visus Therapeutics.

Preeya K. Gupta, MD, has no financial agreements with commercial interests.

Terry Kim, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Allergan, Avedro, Avellino Labs, Azura Ophthalmics, Bausch + Lomb, CorneaGen, Dompé, Eyenovia, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocular Therapeutix, Oculis, Omeros, Presbyopia Therapies, Sight Sciences, Simple Contacts, Surface, and Carl Zeiss Meditec. Stock/Shareholder: Avellino Labs, CorneaGen, Eyenovia, Kala Pharmaceuticals, Ocular Therapeutix, Omeros, Presbyopia Therapies, and Simple Contacts.

Richard Lindstrom, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Allegro, Bausch Health, Kala Pharmaceuticals, Imprimis, Johnson & Johnson Vision, Novartis, Ocular Therapeuix, and Surface Ophthalmics.

Stephen C. Pflugfelder, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Dompé, Kala Pharmaceuticals, Novartis. Grant/Research Support: Dompé.

Elizabeth Yeu, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Avedro, Bausch + Lomb, BioTissue, Beaver Visitec, BlephEx, Bruder, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, LENSAE, Merck, Mynosys, Novartis, Ocular Science, Ocular Therapeutix, Ocusoft, Omeros, Oyster Point Pharma, Science Based Health, Shire, Sight Sciences, Sun Pharma, Surface, Thea, Tarsus, TopCon, TearLab, Visus Therapeutics, and Zeiss. Grant/Research Support: Alcon Vision, BioTissue, Ocular Science, TopCon, and TearLab. Stock/Shareholder: BlephEx, CorneaGen, Melt, Ocular Science, Oyster Point Pharma, and Tarsus.

Edward J. Holland, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Abingworth, Aerie Pharmaceuticals, Akros Pharma, Alcon Vision, Aldeyra Therapeutics, Allegro, Allergan, Azura Ophthalmics, BlephEx, BRIM biotech, Carl Zeiss Medtec, Claris Bio, Corneat, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Glaukos, Hanall, Invirsa, Kala Pharmaceuticals, Mati Therapeutics, Merck, Novartis Pharmaceuticals, Ocular Therapeutix, Ocuphire, Omeros, Oyster Point Pharma, Precise Bio, Prometic Biotherapeutics, ReGentree, Retear, Senju, Shire, Sight Sciences, Slack, Tarsus RX, TearLab, Vomaris, and W.L. Gore and Associates. Speaker’s List: Alcon Vision, Novartis Pharmaceuticals, Omeros, Senju, and Shire. Other Financial/Material Support: Alcon Vision, Mati Therapeutics, Novartis Pharmaceuticals, Omeros, Senju, and Shire.

The staff and planners from Evolve and The Fundingsland Group have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.